Lexicon Pharmaceuticals, Inc.
General ticker "LXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $318.9M (TTM average)
Lexicon Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 53.4%.
Estimated limits based on current volatility of 2.4%: low 1.82$, high 1.91$
Factors to consider:
- Total employees count: 103 (-63.9%) as of 2024
- Top business risk factors: R&D success, Net losses and future profitability, Labor/talent shortage/retention, Intellectual property risks, Product liability
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.81$, 2.29$]
- 2026-12-31 to 2027-12-31 estimated range: [0.83$, 2.30$]
Financial Metrics affecting the LXRX estimates:
- Positive: with PPE of -8.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -15.76 <= 0.07
- Positive: Inventory ratio change, % of -0.18 <= 0
- Positive: Investing cash flow per share per price, % of 26.25 > -0.65
- Positive: Interest expense per share per price, % of 1.94 <= 3.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LXRX quotes
Long-term LXRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.20MM | $31.08MM | $49.80MM |
| Operating Expenses | $172.95MM | $228.20MM | $98.71MM |
| Operating Income | $-171.75MM | $-197.12MM | $-48.91MM |
| Non-Operating Income | $-5.37MM | $-3.29MM | $-1.43MM |
| Interest Expense | $0.00MM | $0.00MM | $8.34MM |
| R&D Expense | $58.89MM | $84.48MM | $61.12MM |
| Income(Loss) | $-177.12MM | $-200.40MM | $-50.34MM |
| Profit(Loss)* | $-177.12MM | $-200.40MM | $-50.34MM |
| Stockholders Equity | $93.11MM | $145.95MM | $107.54MM |
| Inventory | $0.38MM | $0.23MM | $0.28MM |
| Assets | $229.43MM | $298.42MM | $184.99MM |
| Operating Cash Flow | $-161.90MM | $-178.78MM | $-67.85MM |
| Capital expenditure | $0.47MM | $1.03MM | $0.00MM |
| Investing Cash Flow | $-49.94MM | $-15.38MM | $113.02MM |
| Financing Cash Flow | $187.96MM | $238.35MM | $-48.50MM |
| Earnings Per Share** | $-0.80 | $-0.63 | $-0.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.